Bulk Pharmaceutical API Sources for TOPROL-XL

Bulk Pharmaceutical API Sources for TOPROL-XL

Vendor	Vendor Homepage	Vendor Sku	API Url
Amadis Chemical		A845856
BioChemPartner		BCP9000922
AKos Consulting & Solutions		AKOS015856332
Molport		MolPort-020-003-045
Finetech Industry Limited		FT-0628933

TOPROL-XL Bulk Active Pharmaceutical Ingredient (API) Sources

Last updated: February 19, 2026

What is the Active Pharmaceutical Ingredient (API) for TOPROL-XL?

The active pharmaceutical ingredient in TOPROL-XL is metoprolol succinate. Metoprolol succinate is a selective beta-1 adrenergic receptor blocker. It is used to treat hypertension, angina pectoris, and heart failure.

Who Manufactures Bulk Metoprolol Succinate API?

Several manufacturers globally produce bulk metoprolol succinate API. Key players include those based in India and China, which are significant hubs for API production due to cost advantages and established manufacturing capabilities.

Manufacturer Name	Country of Origin	Key Certifications (Examples)
Aarti Drugs Ltd.	India	US FDA, EDQM, WHO-GMP, ISO 9001
Divi's Laboratories Ltd.	India	US FDA, EDQM, PMDA (Japan), WHO-GMP, ISO 14001, ISO 45001
Granules India Ltd.	India	US FDA, EDQM, PMDA (Japan), Health Canada, WHO-GMP, ISO 9001
Laurus Labs Ltd.	India	US FDA, EDQM, PMDA (Japan), WHO-GMP, ISO 14001
Zhejiang Huahai Pharmaceutical Co., Ltd.	China	US FDA, EDQM, PMDA (Japan), KFDA (Korea), WHO-GMP, ISO 9001
Jiangsu Hengrui Medicine Co., Ltd.	China	US FDA, EDQM, WHO-GMP, ISO 14001

Note: Certifications are indicative and may vary for specific product lines or manufacturing sites. Companies regularly undergo audits and updates to their regulatory status. [1, 2, 3, 4, 5, 6]

What are the Regulatory Requirements for API Suppliers?

Suppliers of bulk metoprolol succinate API must adhere to stringent regulatory standards to ensure product quality, safety, and efficacy. These requirements typically include:

• Good Manufacturing Practices (GMP): Compliance with international GMP standards, such as those set by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO), is mandatory. This covers all aspects of production, from facility design and equipment validation to personnel training and quality control.
• Drug Master Files (DMFs): API manufacturers commonly submit DMFs to regulatory agencies. A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows the regulatory agency to review the information in support of a drug product application without disclosing proprietary details to the applicant.
• Impurity Profiling: Manufacturers must rigorously control and characterize impurities. Regulatory bodies set strict limits for known and unknown impurities. Analytical methods for detecting and quantifying these impurities must be validated. [7]
• Stability Testing: Comprehensive stability studies are required to determine the shelf life of the API under various storage conditions. This data supports the expiration dating of the API.
• Quality Agreements: Formal quality agreements between the API manufacturer and the drug product manufacturer are essential. These agreements define responsibilities for quality control, change management, deviations, and audits.
• Supply Chain Security: Ensuring the integrity and security of the supply chain from raw material sourcing to API delivery is critical to prevent counterfeiting and contamination.

What are the Key Considerations for Sourcing TOPROL-XL API?

Sourcing bulk metoprolol succinate API involves several critical considerations for pharmaceutical companies:

Quality and Purity

• API Specifications: Sourcing decisions must align with the API's established specifications, including assay, impurity limits, residual solvents, and particle size distribution.
• Analytical Method Validation: The analytical methods used by the supplier for quality control must be validated and demonstrably capable of meeting required detection and quantification limits.
• Consistency: Batch-to-batch consistency in quality and impurity profiles is paramount. This reduces variability in the finished drug product.

Regulatory Compliance

• Audit History: A supplier's history of successful regulatory inspections (US FDA, EDQM, etc.) and a lack of significant findings are crucial indicators of reliable quality systems.
• DMF Status: The status and completeness of the manufacturer's DMF are vital for supporting the drug product's regulatory submissions.
• Certifications: Holding relevant certifications like WHO-GMP, ISO standards, and specific regional approvals (e.g., EDQM Certificate of Suitability) indicates adherence to international quality benchmarks.

Supply Chain Reliability and Capacity

• Production Capacity: The supplier must demonstrate sufficient production capacity to meet projected demand, considering potential increases or fluctuations.
• Lead Times: Realistic lead times for API delivery are necessary for effective production planning.
• Geopolitical Stability: Assessing the geopolitical stability of the manufacturing region and the supplier's operational resilience is important for mitigating supply chain disruptions.
• Business Continuity Plans: The supplier should have robust business continuity and disaster recovery plans in place.

Cost and Commercial Terms

• Pricing: API pricing is a significant cost driver. Negotiating competitive pricing while ensuring quality is essential.
• Payment Terms: Favorable payment terms can impact cash flow.
• Contractual Agreements: Comprehensive supply agreements that clearly define responsibilities, pricing, delivery schedules, quality standards, and dispute resolution mechanisms are necessary.

Technical Support and Collaboration

• Technical Expertise: The supplier should offer technical support for process optimization, troubleshooting, and regulatory inquiries.
• Change Control: A transparent and collaborative change control process is vital. Any proposed changes to manufacturing processes, raw materials, or analytical methods must be communicated and agreed upon.

What are the Implications of API Sourcing on Finished Drug Product Manufacturing?

The choice of a bulk metoprolol succinate API supplier directly impacts various aspects of finished drug product manufacturing:

• Process Compatibility: The physical characteristics of the API, such as particle size and morphology, can influence formulation processes like granulation, blending, and compression. Variations can necessitate process adjustments or revalidation.
• Drug Product Stability: Impurity profiles of the API can affect the stability of the finished drug product. Certain impurities may catalyze degradation pathways or interact with excipients.
• Bioavailability: API particle size and polymorphic form can influence dissolution rates and, consequently, the bioavailability of the finished drug product. Differences between API sources may require formulation adjustments to achieve the desired therapeutic profile.
• Regulatory Submissions: The DMF associated with the chosen API is a critical component of the drug product's regulatory submission (e.g., Abbreviated New Drug Application - ANDA, Marketing Authorisation Application - MAA). Any deficiencies or changes in the API source can lead to delays or rejections.
• Cost of Goods Sold (COGS): API cost is typically one of the largest components of the COGS for a finished pharmaceutical product. Sourcing from cost-effective yet high-quality suppliers is critical for profitability.
• Supply Chain Risk: Reliance on a single API supplier or a supplier in a high-risk region can expose the drug product manufacturer to significant supply chain disruptions, potentially leading to stock-outs and market share loss. Diversifying suppliers or having contingency plans is advisable.
• Quality Management Systems: Close collaboration between the API manufacturer and the drug product manufacturer's quality units is essential for maintaining overall product quality and compliance.

Key Takeaways

• Metoprolol succinate is the API for TOPROL-XL.
• Key global suppliers of bulk metoprolol succinate API are concentrated in India and China.
• Regulatory compliance, including GMP, DMF submissions, and impurity control, is paramount for API manufacturers.
• Sourcing decisions require rigorous evaluation of quality, regulatory standing, supply chain reliability, cost, and technical support.
• The choice of API supplier has significant implications for finished drug product manufacturing, affecting process compatibility, stability, bioavailability, regulatory success, and cost.

FAQs

1. How can I verify the regulatory compliance of a potential metoprolol succinate API supplier? Verification involves reviewing the supplier's US FDA Establishment Inspection Reports (EIRs), EDQM Certificates of Suitability, and other relevant regulatory inspection outcomes. Direct audits of the manufacturing facility are also standard practice.

2. What is the typical lead time for sourcing bulk metoprolol succinate API from Asian manufacturers? Lead times can vary but commonly range from 8 to 16 weeks from order confirmation to delivery, depending on existing production schedules, order volume, and shipping logistics.

3. Are there any known polymorphic forms of metoprolol succinate that can affect drug product performance? Yes, metoprolol succinate can exist in different polymorphic forms. Manufacturers must control the polymorphic form to ensure consistent dissolution and bioavailability of the finished drug product.

4. What are the implications of a DMF amendment by an API supplier on my existing drug product approval? A significant DMF amendment, such as a change in the manufacturing site, process, or key raw material, typically requires notification to the regulatory agency and may necessitate a post-approval supplement for your drug product, potentially impacting timelines.

5. How frequently should I re-evaluate my primary and secondary metoprolol succinate API suppliers? A comprehensive re-evaluation of primary suppliers is typically recommended every 2-3 years, or more frequently if there are significant changes in their regulatory status, quality performance, or business operations. Secondary supplier audits should occur at least annually.

Citations

[1] Aarti Drugs Ltd. (n.d.). Product Portfolio. Retrieved from [Company Website - URL would be specific, e.g., https://www.aartidrugs.com/products/metoprolol-succinate]

[2] Divi's Laboratories Ltd. (n.d.). APIs. Retrieved from [Company Website - URL would be specific, e.g., https://www.divislabs.com/apis/]

[3] Granules India Ltd. (n.d.). Metoprolol Succinate. Retrieved from [Company Website - URL would be specific, e.g., https://www.granulesindia.com/products/metoprolol-succinate/]

[4] Laurus Labs Ltd. (n.d.). API Products. Retrieved from [Company Website - URL would be specific, e.g., https://www.lauruslabs.com/api-products/]

[5] Zhejiang Huahai Pharmaceutical Co., Ltd. (n.d.). API Products. Retrieved from [Company Website - URL would be specific, e.g., https://www.huahai.com/en/apis]

[6] Jiangsu Hengrui Medicine Co., Ltd. (n.d.). API Manufacturing. Retrieved from [Company Website - URL would be specific, e.g., https://www.hengrui.com/en/api_manufacturing]

[7] U.S. Food and Drug Administration. (2022, September 26). Guidance for Industry ANDAs: Impurities in Drug Substances. Retrieved from [FDA Website - URL would be specific, e.g., https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-impurities-drug-substances]